Introduction
============

T-cell lymphomas encompass several hematological cancers in children and adolescents. Arising in cells of the innate and adaptive immune systems, T- and natural killer (NK)-cell neoplasms comprise over 20 distinct entities in the current World Health Organization (WHO) schema ([Table 1](#tbl1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).^[@bib1],\ [@bib2]^ The most common types in pediatric patients are T-cell lymphoblastic lymphoma (T-LBL) and anaplastic large cell lymphoma (ALCL). Of the other rarely occurring pediatric T-cell neoplasms, peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) is seen most frequently. Most of these lymphomas are aggressive diseases^[@bib3]^ that present formidable diagnostic and therapeutic challenges.^[@bib4]^ In this review, we update the biologic features of several T-cell lymphomas in children and adolescents, with a focus on their molecular pathology and its implications for novel therapeutics.

T-LBL in children and adolescents
=================================

After Burkitt lymphoma, LBL is the second most common pediatric non-Hodgkin lymphoma (NHL). In 80--90% of LBL, disease is T-cell lineage, unlike acute lymphoblastic leukemia (ALL) where precursor B-cell is typical. Thus, T-LBL is the most common pediatric T-cell lymphoma.^[@bib5],\ [@bib6],\ [@bib7]^ Historically, T-LBL and T-ALL have been considered variant clinical manifestations of the same disease, but genomic and gene expression studies reveal molecular differences between T-LBL and T-ALL.^[@bib8],\ [@bib9]^ Clinical features also subtly differentiate these cancers, with T-LBL tending to have earlier and local relapses, and T-ALL more often having central nervous system (CNS) involvement at diagnosis.^[@bib10],\ [@bib11],\ [@bib12]^

Children with T-LBL frequently present with supra-diaphragmatic mass. Overlapping symptoms in T-LBL and T-ALL derive from their shared propensity to manifest with hepatic, splenic, and nodal enlargement, as well as with mediastinal mass. Serious sequelae from these clinical features can occur, including obstructive airway compromise and superior vena cava syndrome; both may require emergent glucocorticoid and/or radiation therapy.^[@bib13]^ T-LBL is often advanced at diagnosis (stage III--IV), unlike B-cell LBL, which primarily is a localized disease of skin, bone, or lymph node. Accordingly, stage I and II T-LBLs are relatively rare. As no molecular features can yet reliably differentiate LBL from ALL, the clinical finding of ⩾25% of marrow infiltration by malignant lymphoblasts continues to define ALL, while 5--25% marrow involvement is regarded as stage IV LBL.^[@bib14]^

Current treatments for pediatric T-LBL
--------------------------------------

Children with limited disease (stage I--II) T-LBL do well, with long-term overall survival (OS) of 85--90%.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib14]^ Disease-free survival is lower at 63--73%, but relapsed patients show good responses to salvage therapy.^[@bib15]^ As in advanced-stage T-LBL, ALL protocols are the basis of treatment for T-LBL patients with localized disease.^[@bib16]^ These patients are treated without local surgery or radiation, and do not receive craniospinal radiation therapy (CRT) prophylaxis. The following discussion will focus on therapies for advanced (stage III--IV) T-LBL patients.

Advanced pediatric T-LBL outcomes improved dramatically on the 10-drug LSA~2~L~2~ regimen.^[@bib17]^ Most LBL therapies can be traced to this protocol, with nearly all current strategies comprised of induction, consolidation, re-intensification, and maintenance phases. The specific timing and doses of some agents may vary, but overall, treatments since 2000 have achieved 70--90% event-free survival (EFS) with 12- to 24-month regimens ([Table 2](#tbl2){ref-type="table"}).

Many treatment protocols advanced LBL therapy over the past 15 years; highlights of these studies are briefly summarized: The German Berlin--Frankfurt--Munster (BFM)-90 regimen administered CRT to all advanced patients, independent of CNS involvement. Although EFS was 90% in stage III--IV patients, long-term effects prompted ensuing studies to apply CRT to only CNS-positive patients.^[@bib11]^ The Italian lymphoma non-Hodgkin (LNH)-92 protocol reported only 69% EFS in advanced T-LBL, but this regimen lacked re-intensification, demonstrating the value of this phase.^[@bib18]^ The BFM-95 study queried whether systemic methotrexate (MTX) and intrathecal (IT) chemotherapy could safely replace CRT as prophylaxis for CNS recurrence. Although its 84% EFS was lower than the 90% EFS of BFM-90, comparison with other earlier BFM studies determined that omitting CRT was not inferior to prior regimens that applied CRT to CNS-negative patients.^[@bib19]^ The Children\'s Oncology Group (COG) used an intense and truncated (12-month) multi-agent protocol for advanced T-LBL. This yielded a 78% EFS, similar to longer ALL-based regimens.^[@bib20]^ Early reports from the current COG study testing high-dose MTX and early intensification suggest that neither intervention improves EFS.^[@bib21]^

Two studies have explored completely omitting CRT in advanced disease, including CNS-positive patients.^[@bib22],\ [@bib23]^ A European Organization for Research and Treatment of Cancer (EORTC) trial showed omission of CRT did not raise CNS relapse rates, with 78% 6-year EFS. Although only three CNS-positive patients participated in this trial, the overall low rate of CNS relapse validates that intrathecal treatments can safely replace CRT in stage III--IV, CNS-negative patients. This study also identified response to a prednisone-only prephase as an important prognostic factor. Patients in complete remission (CR) after prephase (16/121 patients) had 100% EFS, but only 14% EFS was seen in prednisone-resistant T-LBL.^[@bib22]^ St Jude\'s NHL13 trial also eliminated CRT. Like their institutional ALL regimen, NHL13 used high-dose MTX every 8 weeks and added a re-induction phase during maintenance. This study had an impressive 83% EFS in advanced T-LBL, despite its lack of CRT.^[@bib23]^

Therapies for relapsed pediatric T-LBL
--------------------------------------

Historically, children with refractory or relapsed LBL have poor prognoses, with 10% 5-year OS.^[@bib24]^ Most relapses occur within 2 years of diagnosis ([Figure 2](#fig2){ref-type="fig"}).^[@bib10]^ Successful outcomes have been reported in recurrent T-LBL using intense re-induction chemotherapy followed by either autologous (auto-) or allogeneic stem cell transplant (allo-SCT), but these series each contained 10 or fewer T-LBL patients, so reliable survival figures are not available.^[@bib25],\ [@bib26],\ [@bib27]^ Modestly effective re-induction regimens include ICE (ifosfamide, carboplatin, and etoposide; 92% response rate seen in a 40 patient cohort containing 24 relapsed NHL) and DECAL (dexamethasone, etoposide, cisplatin, high-dose cytarabine and [L]{.smallcaps}-asparaginase; 50% response rate in a 58 patient NHL cohort, including 26 LBL cases).^[@bib28],\ [@bib29]^

Chemo-sensitive relapses have better outcome after auto or allo-SCT.^[@bib28],\ [@bib30]^ Relapses after allo-SCT were less common in a group of 204 LBL patients (most of whom had T-LBL), but higher transplant-related mortality was felt to offset any survival benefit.^[@bib31]^ However, this remains an open question. In one relapsed T-LBL BFM cohort, OS was quite low (14% 4/28 patients), but all 4 long-term survivors received allo-SCT. Yet, because only 2 patients received auto-SCT in this study (9 received allo-SCT and 17 chemotherapy-only), these data do not convincingly favor allo- over auto-SCT.^[@bib10]^ However, other studies imply that graft vs lymphoma effect after allo-SCT may help prevent relapses. Specifically, one series of 53 refractory or recurrent LBL patients showed much higher EFS after allo- compared with auto-SCT (40% vs 4%).^[@bib32]^ A second study of 48 refractory or relapsed LBL patients (32 with T-LBL) also demonstrated higher EFS and OS in the allo-SCT group.^[@bib33]^ Although neither study examined T-LBL exclusively, their large sample sizes and the preponderance of T-cell disease within LBL both suggest that results are likely generalizable to T-LBL.

Future therapies for pediatric T-LBL
------------------------------------

To date, new therapies for T-LBL are limited. The novel purine analog nelarabine shows promise in relapsed and refractory T-ALL, but not T-LBL.^[@bib34]^ Impetus for the use of nelarabine in T-cell cancer was suggested by the finding that purine nucleoside phosphorylase-deficient patients develop T-cell cytopenias because of toxic deoxyguanosine triphosphate levels in T cells. As a deoxyguanosine triphosphate derivative, nelarabine resists purine nucleoside phosphorylase-mediated degradation and shows marked T-lymphocyte toxicity. In a phase II COG study, T-ALL patients in first relapse had a 55% response rate, and 48% of patients achieved CR. Unfortunately, nelarabine lacked similar efficacy in T-LBL, and 18% of patients exhibited severe (⩾ grade 3) CNS toxicity, such as peripheral neuropathy, hallucinations, and seizures.^[@bib34]^ Other novel agents targeting frequent NOTCH1 and mammalian target of rapamycin (mTOR) kinase upregulation in T-LBL are being investigated *in vitro*. Finally, phase I studies are also testing another purine nucleoside phosphorylase inhibitor, forodesine, in T-cell malignancy. However, these trials investigate adults with PTCL rather than pediatric T-LBL.^[@bib35]^

As salvage rates for relapsed T-LBL are dismal and promising novel agents do not exist, delineating prognostic factors that predict relapse would be useful in stratifying high-risk patients for intensified upfront treatment regimens. Currently, such factors are not well established in pediatric T-LBL. Aside from the striking EORTC result where response to a 1-week prednisone pre-phase predicted opposite extremes in EFS, other clinical prognostic factors are lacking. Assessment of treatment responses via laboratory testing, molecular studies, or radiographically (such as 2-deoxy-2-\[18F\]fluoro-[D]{.smallcaps}-glucose positron emission tomography) are all tenable options to identify high-risk patients early-on.^[@bib36]^

The paucity of cytogenetic and molecular features linked to T-LBL clinical response presents intriguing opportunities for study. One recent discovery is the finding that chromosome 6q loss of heterozygosity in T-LBL predicts a higher risk of relapse, but other cryptic karyotypic features may also exist.^[@bib8]^ Meanwhile, our assessment of low-level minimal disseminated disease (MDD) and minimal residual disease is also improving, with T-cell receptor (TCR) PCR assays able to quantify these reliably.^[@bib37]^ Flow cytometry can also detect occult disease, and these two techniques have been compared with respect to their detection and quantification of MDD and minimal residual disease in T-LBL.^[@bib38]^ In a separate study using a 0.01% MDD threshold, two-thirds of patients had MDD-positive marrow at diagnosis ([Figure 3a](#fig3){ref-type="fig"}). Critically, patients with high marrow MDD had much lower 2-year EFS (52%) than patients with \<5% MDD (EFS=89% [Figure 3b](#fig3){ref-type="fig"}). These data clearly demonstrate poor outcomes in stage III patients with higher MDD.^[@bib39]^ However, prior BFM studies have shown no prognostic difference between stage III and IV T-LBL patients.^[@bib19]^ Similarly, stage IV patients with gross marrow disease (6--24% blasts) treated with COG-based therapy greatly exceed the poor 2-year EFS seen in these high-MDD stage III patients.^[@bib20]^ This curious contradiction alludes to important questions that remain in T-LBL biology. Further study of the aforementioned predictors and discovery of new prognostic features will permit prospective studies to determine which at-risk groups may benefit from intensified treatments, like allo-SCT, as first-line approaches.

For instance, a new T-ALL type was recently described with markedly poor prognosis, raising the question of whether this group might also be relevant to T-LBL.^[@bib40]^ This new type, dubbed early T-cell precursor ALL (ETP-ALL), has distinct biology from classic precursor T-ALL. ETP-ALL retains stem-cell features and has high genomic instability. In a cohort of over 200 T-ALL cases, over 12% met ETP-ALL criteria. These patients had higher minimal residual disease during induction ([Figure 4a](#fig4){ref-type="fig"}) and increased rates of induction failure and relapse ([Figure 4b](#fig4){ref-type="fig"}).^[@bib40]^ To optimally treat these patients, St Jude\'s now performs allo-SCT in first remission for ETP-ALL. Analyses of T-LBL specimens are needed to determine if 'ETP-LBL\' exists, and if so, whether a similar therapeutic strategy might be warranted.

Molecular basis of T-cell lymphoblastic neoplasia and therapeutic implications
------------------------------------------------------------------------------

Patients with T-LBL and T-ALL present similar challenges, so understanding the molecular origins of these diseases is vital for efforts to develop better treatment outcomes. It is generally accepted that malignant transformation is a multistep process of genetic mutations that arrest differentiation and allow uncontrolled cell growth.^[@bib41],\ [@bib42]^ In T-lymphoblastic cancers, these genetic events have been queried extensively.^[@bib43],\ [@bib44]^ T-LBL and T-ALL share some cytogenetic and molecular features, implying these diseases are closely related neoplasms.^[@bib41]^ As most analyses of T-lymphoblastic neoplasia have studied T-ALL, not all of this impressive body of work may apply to T-LBL. However, efforts have been undertaken to compare the genetic and genomic origins of these related diseases, and they reveal both shared features and potentially important differences.^[@bib45],\ [@bib46]^

Juxtaposition of the *TCRβ* or *TCRαδ* enhancers with proto-oncogenes via chromosomal translocations can mis-activate many transcription factors or repressors.^[@bib47]^ Such TCR-driven translocations are seen in about 33% of T-ALL cases, and dysregulate basic helix-loop-helix and homeobox transcription factors, LIM-only domain transcriptional regulators, or other oncogenes like *NOTCH1* and *MYB*. Non-TCR translocations are also described which create oncogenic fusion proteins such as *MLL-ENL*, *CALM-AF10*, and *SET-NUP214*.^[@bib48],\ [@bib49]^

Expression profiling in T-ALL supports the paradigm that oncogenic transcription factors can disrupt the normal pathways governing cell proliferation, differentiation, and survival during T-cell development.^[@bib50],\ [@bib51],\ [@bib52]^ As specific translocations and expression patterns are associated with T-cell developmental arrest at distinct stages, it is believed that these genetic events can define different molecular subtypes of T-ALL.^[@bib44]^

However, two other common genetic lesions are present across many T-ALL subtypes. The most prevalent genetic abnormality in T-ALL is inactivation of *CDKN2A* and *CDKN2B* at chromosome 9p21. Deletions at this locus occur in \>70% of T-ALL.^[@bib53]^ Another frequent aberration is activating mutation(s) in the *NOTCH1* proto-oncogene, which are seen in over half of T-ALL cases.^[@bib54]^ Other rare but recurrent genetic lesions in T-ALL include mutations activating *JAK1, FLT3*, and *RAS*,^[@bib55],\ [@bib56],\ [@bib57]^ or inactivating the tumor suppressors *NF1, PTEN*, and *WT1*.^[@bib58],\ [@bib59],\ [@bib60]^ Mutations in these genes are infrequent, so it is not yet clear whether they occur in several T-ALL types like *CDKN2A*/*N2B* and *NOTCH1*.

NOTCH1 activation is important to T-ALL pathogenesis. NOTCH1 normally promotes T-cell lineage commitment by lymphoid progenitors,^[@bib61]^ and blocking its signaling in progenitors impedes T-cell development, instead favoring the B-cell lineage.^[@bib62],\ [@bib63]^ A role for *NOTCH1* in T-ALL was first suspected because of a rare translocation, t(7;9)(q34;q34.3). This rearrangement coupled the *TCRβ* locus to ICN1, the IntraCellular portion of NOTCH1, a constitutively active form of the protein.^[@bib64]^ NOTCH1\'s role was further substantiated by animal models where NOTCH1 and ICN1 can induce T-ALL and T-LBL *in vivo*.^[@bib65],\ [@bib66]^

Scrutiny of the NOTCH1 pathway has led to a novel therapeutic strategy. Cell surface NOTCH1 undergoes proteolysis to generate active ICN1, including a cleavage by the enzyme gamma-secretase. Consequently, gamma-secretase inhibitors (GSIs) inhibit NOTCH1 signaling ([Figure 5](#fig5){ref-type="fig"}). GSIs block growth in some T-ALL cell lines and cause cell cycle arrest and apoptosis of primary T-ALL cells.^[@bib54],\ [@bib67]^ Added to glucocorticoids, GSIs show potent anti-T-ALL effects *in vivo*, and also diminish the gastrointestinal toxicity seen with GSIs alone. Combining GSIs with glucocorticoids can also induce apoptosis in previously glucocorticoid-resistant T-ALL.^[@bib68]^ Unfortunately, loss of the tumor-suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) confers GSI resistance to T-ALL cell lines.^[@bib59]^ However, as *PTEN*-null T cells are highly sensitive to AKT inhibitors, combined NOTCH1 and phosphatidylinositol 3-kinase (PI3K)/AKT therapies are also being investigated in T-ALL.^[@bib59],\ [@bib69]^

Targeting of the mTOR pathway is similarly being explored, as simultaneous GS- and mTOR-inhibition shows synergy in T-ALL.^[@bib70],\ [@bib71]^ Similarly, because NOTCH1 regulates nuclear factor kappaB (NF-κB) signaling, GSIs synergize with bortezomib, which inhibits NF-κB ([Figure 5](#fig5){ref-type="fig"}).^[@bib72]^ Another target of NOTCH1 is *CCR7*, a chemokine receptor that mediates CNS infiltration by T-ALL.^[@bib73]^ As the CNS represents a relatively common site of relapse, GSIs may be able to prevent CNS recurrence. Although promising, clearly, it remains to be seen whether these ideas will improve T-ALL outcomes, and if they can be extrapolated to T-LBL treatment.

*CDKN2A*/*N2B* and *NOTCH1* mutations are prevalent in T-ALL, but not universal. Thus, they fall short of an absolute molecular explanation for all T-lymphoblast transformation. Given the vast diversity of additional aberrations already described, it is likely that other genetic lesions in T-cell malignancy are yet to be identified. Certainly, future discoveries may generate further therapeutic options. Notably, additional animal models of T-LBL offer promising new tools to expand our knowledge of the molecular basis of this disease.^[@bib66],\ [@bib74],\ [@bib75]^

ALCL in children and adolescents
================================

ALCL comprises about 10% of pediatric NHL. It was recognized as a distinct disease in the 1980s,^[@bib76]^ and much of its biology is now understood.^[@bib77]^ ALCL has two presentations: systemic ALCL and primary cutaneous ALCL occurring exclusively in skin.^[@bib78]^ Categorized as a mature T-cell lymphoma, most ALCLs have *TCR* gene rearrangements even if they lack T-cell antigen expression.^[@bib79]^ In children and adolescents, systemic ALCL is associated with anaplastic lymphoma kinase (*ALK*) gene translocations, denoting the disease as *ALK*^*+*^. The most common translocation creates an *NPM--ALK* fusion gene that joins the nucleophosmin gene upstream to *ALK*. Less common translocations fusing *ALK* downstream of other partners are also described ([Table 3](#tbl3){ref-type="table"}).^[@bib80]^ Both expression profiling and genomic analyses of ALCL suggest that *ALK*^*+*^ and *ALK*^*−*^ lymphomas actually represent distinct clinical entities.^[@bib81],\ [@bib82]^ Accordingly, *ALK*^*+*^ and *ALK*^*−*^ lymphomas are treated differently and have differing prognoses. Apart from *ALK*^*−*^ cutaneous ALCL, which can be successfully managed by surgery alone, *ALK*^*+*^ disease has better outcomes, and this distinction stratifies patients to receive less-intensified therapy.

ALCL is characterized histologically by large, pleomorphic, and multinucleate 'hallmark cells,\' with horseshoe nuclei, abundant cytoplasm, and peri-nuclear eosinophilia.^[@bib83]^ Hallmark cells may resemble Reed--Sternberg cells of Hodgkin lymphoma (HL), but have less conspicuous nucleoli. Morphologic ALCL variants include the common variant (75%) composed chiefly of hallmark cells, the lymphohistiocytic variant (10%) with benign histiocytes admixed with neoplastic cells, and a small cell variant (10%) of primarily small neoplastic cells and only scattered hallmark cells.^[@bib84]^ Other subtypes (\<5%) include sarcomatoid, signet ring, neutrophil-rich, and giant cell variants.^[@bib79]^

Pediatric and adult ALCL have several differences. Over 90% of childhood ALCL is *ALK*^*+*^,^[@bib79]^ compared with only 60% of adult ALCL.^[@bib85]^ Also, primary cutaneous ALCL is nearly always *ALK*^*−*^, and rare in children.^[@bib80]^ Children typically present with advanced stage disease. A compendium of 225 childhood ALCL patients treated on BFM, SFOP, or UKCCSG protocols revealed that 74% were stage III--IV by St Jude criteria and 75% were Ann Arbor stage III or IV. Extranodal disease was common (68%), with skin (26%), bone (14%), and soft-tissues (15%) all relatively frequently involved.^[@bib86]^ B symptoms were seen in 54%, consistent with prior reports.^[@bib86],\ [@bib87]^ Despite these aggressive features, both marrow and CNS invasion are uncommon in pediatric ALCL, occurring in \<10% and \<5% of cases, respectively.^[@bib85],\ [@bib86],\ [@bib88]^

Current treatments for pediatric ALCL
-------------------------------------

The optimal approach for limited disease is not established, as both B-NHL and T-ALL regimens show similar efficacy. EFS may be as high as 100% for children with localized ALCL (stage I--II resected) as shown in the NHL-BFM-90 trial using 2 months of combined chemotherapy.^[@bib89]^ Previously, St Jude\'s reported 75% EFS in children with localized CD30^+^ large cell lymphoma (presumably ALCL) treated with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), either with or without maintenance therapy.^[@bib90]^

Advanced pediatric ALCL treatment has evolved over the past two decades. Different strategies have achieved 65--75% EFS with either B-NHL protocols or LSA~2~L~2~-type therapies ([Table 4](#tbl4){ref-type="table"}).^[@bib89],\ [@bib91],\ [@bib92],\ [@bib93],\ [@bib94],\ [@bib95]^ Other trials have used a doxorubicin, prednisone, and vincristine (APO) backbone. Pediatric Oncology Group (POG)-9315 added intermediate-dose MTX and high-dose cytarabine to APO, but this did not improve efficacy, with MTX and cytarabine causing greater toxicity. Children on the APO-only arm had 75% 2-year EFS.^[@bib92]^ COG is evaluating the addition of weekly vinblastine to APO. This stems from encouraging French data in relapsed ALCL, where 10/12 patients responded to weekly vinblastine.^[@bib96]^ Unfortunately, a recent COG report showed merely worse myelosuppression with vinblastine, with an equivalent 77% 2-year EFS.^[@bib97]^

The European intergroup ALCL99 trial, which is based on the BFM B-NHL treatment strategy, employed a less toxic regimen with high-dose MTX and no IT therapy. They reported 74% 2-year EFS and diminished toxicity.^[@bib98]^ Until ALCL99, CNS-negative ALCL treatment usually included IT prophylaxis. With their recent success in preventing CNS relapse without IT treatment, perhaps reducing the number of high-dose MTX administrations should also be considered. For rare ALCL patients with CNS disease, CRT doses of 18--24 Gy, in addition to high-dose MTX and/or cytarabine plus IT chemotherapy, has been used.^[@bib89],\ [@bib91]^

Several prognostic factors have been identified in children with ALCL. Clinical features associated with poor outcome include visceral organ (liver, lung, or spleen) or mediastinal involvement, elevated lactate dehydrogenase (LDH), and diffuse skin disease.^[@bib86],\ [@bib91],\ [@bib99]^ In addition, correlation between ALCL biology and outcome is now possible via PCR-based MDD detection of the *NPM-ALK* transcript. Higher levels of this mRNA in marrow predicted a 71% chance of relapse, in contrast to 18% in MDD-negative patients.^[@bib100]^ Meanwhile, detection of endogenous anti-*ALK* antibodies are inversely correlated to ALCL dissemination and risk of relapse in *ALK*^*+*^ disease, implying that ALK may be a potential immunotherapeutic target.^[@bib101],\ [@bib102]^ Additional results from the recent ALCL99 trial reveal that two less common ALCL variants, small cell and lymphohistiocytic, have a high risk of treatment failure, independent of clinical risk factors.^[@bib103]^ Further advances in our ability to identify patients at high risk for relapse will enable appropriate application of intensified front-line therapies to potentially improve outcomes.

Relapsed ALCL is quite different from other pediatric NHL subtypes. Chemosensitivity of recurrent disease is a hallmark of childhood ALCL, rendering salvage strategies generally effective.^[@bib104],\ [@bib105]^ Clinical behavior after relapse varies from aggressive to indolent, with a waxing and waning course.^[@bib106]^ Historically, ALCL has been considered prone to late relapse, like other lymphomas seen in adult patients.^[@bib107]^ However, a recent report describing 74 children and adolescents with recurrent ALCL revealed a median time of only 7.1 months between diagnosis and relapse. Of 58 patients who achieved remission after front-line therapy, only 18 recurred \>1 year from original diagnosis.^[@bib108]^ The prognostic significance of early vs late ALCL relapse remains an open question, with recurrences \>1 year after diagnosis perhaps having superior outcome,^[@bib96]^ but this finding has not been consistent in all cohorts.^[@bib109]^ Late relapse again showed trends of better EFS and OS in the most recent report,^[@bib108]^ but because these studies all compile data from patient groups who received differing initial treatments and relapse therapies, no definitive answer is yet available.

In a series of three French clinical trials over two decades, relapse therapies varied widely from single-agent vinblastine to multi-agent treatment to fully ablative chemotherapy with auto- or allo-SCT. Early relapses and failures with intensive initial regimens carry higher risk for treatment failure. Three-year disease-free survival did not differ in patients who received ablative SCT in CR2 vs chemotherapy alone.^[@bib96],\ [@bib110]^ However, recent studies using allo-SCT in relapsed and refractory ALCL are promising, with 75% 3-year EFS seen in one 20 patient cohort.^[@bib111],\ [@bib112]^

Progress in ALCL treatment lies in both new targeted agents and optimizing risk stratification to identify patients who may benefit from front-line allo-SCT. The CD30 antigen is one compelling novel therapeutic target. Present in nearly all cases of childhood and adolescent ALCL, CD30 expression is controlled by *ALK* ([Figure 6](#fig6){ref-type="fig"}). SGN-35, an anti-CD30 monoclonal antibody, has shown even greater success than its predecessor SGN-30.^[@bib113],\ [@bib114]^ Phase I trials have examined SGN-35 monotherapy in patients with refractory/recurrent CD30^+^ ALCL and HL.^[@bib115]^ Dose-limiting toxicities (thrombocytopenia, hyperglycemia, and febrile neutropenia) were used to derive a treatment dose of 1.8 mg/kg given every 3 weeks. At this dose, SGN-35 was generally well tolerated, with patients exhibiting primarily grade 1 or 2 adverse effects consisting of fatigue, nausea, neutropenia, and peripheral neuropathy (33% of patients) as well as fever, headache, back pain, and cough (25% of patients).^[@bib115]^ At higher doses, one trial showed 7/8 patients achieving CR. In a second trial, also at higher SGN-35 doses, 7/28 patients achieved CR with an overall response rate (ORR) of 46%.^[@bib116],\ [@bib117]^ These responses to monotherapy in heavily pre-treated patients offer exciting hope that adding SGN-35 to combination therapy will yield even better results in front-line therapy.

Development of other novel therapeutics has been fostered by advances in understanding of ALCL biology. Targets include the *ALK* protein itself, via small molecule and antibody-mediated inhibition. The ALK inhibitor NVP-TAE684 both prevented tumors and promoted pre-induced tumor regression in separate mouse models.^[@bib118]^ Another kinase inhibitor, the dual MET/ALK inhibitor Crizotinib, also shows promise in *ALK*^*+*^ ALCL. Spurred on by the finding that some non-small cell lung carcinoma patients have a related translocation involving the *ALK* gene (*EML4-ALK*), Crizotinib is being developed as a targeted agent for cancers driven by constitutive ALK activity and was recently approved by the FDA in patients with lung cancer with the presence of an ALK mutation. Exciting results with this medication in refractory and relapsed *ALK*^*+*^ ALCL suggest this strategy holds great clinical promise.^[@bib119]^

These data with ALK inhibitors agree with findings that circulating anti-ALK antibodies predict lower relapse rates, and have led to vaccination studies using the ALK antigen.^[@bib120]^ Other investigations have focused on different aspects of ALCL biology. Although somatic mutations in ALCL are rare, sequencing identified 6 different mutations in 12/44 (27%) patients with *ALK*^*+*^ ALCL. Perforin (*PRF1*) mutations were particularly prevalent in ALCL, compared with control subjects where the A91V mutation was infrequently seen (*P*\<0.01).^[@bib121]^ *PRF1* mutations occur in other NHLs, and may impair cytotoxicity because of abnormal PRF1 conformation caused by the A91V mutation.^[@bib122]^ Additionally, amplification of the sonic hedgehog (*SHH*) gene in a subset of *ALK*^*+*^ ALCL^[@bib123]^ has been shown to lead to dysregulated *SHH* signaling.

Proteomic analyses of ALCL complement these landmark genomic studies and have been instrumental in understanding the ALK protein network.^[@bib124],\ [@bib125]^ Proteomic signatures from cells expressing the *NPM--ALK* fusion show alterations in cellular processes including proliferation, ribosome synthesis, survival, apoptosis, angiogenesis, and cyto-architectural organization.^[@bib124]^ Further studies revealed loss of cell adhesion caused by *NPM-ALK* expression in a kinase-dependent manner, as well as sensitivity of *ALK*^*+*^ ALCL to inhibition of the RAS, extracellular signal-regulated kinase (ERK) and FK506 binding protein-rapamycin-associated protein (FRAP) mTOR signaling pathways.^[@bib124]^ Understanding the myriad effects of *NPM-ALK* on these cellular pathways offers key insights into *ALK*^*+*^ ALCL biology.

Several potential therapeutic targets in ALCL have also been identified by proteomic studies. Constitutive CD25 expression by pediatric ALCL has led to *in vitro* investigations of the anti-CD25 agent, denileukin diftitox.^[@bib126],\ [@bib127]^ Identification of other downstream pathways interconnected with ALK has led to studies examining disruption of *ALK*-associated pathways. Heat shock protein 90 (*Hsp-90)* and the PI3K/Akt pathway both have interactions with the ALK protein network. *In vitro* studies targeting *Hsp-90* cause increased degradation of *NPM-ALK* and apoptosis of ALCL cell lines,^[@bib128]^ while PI3K/Akt-null mice injected with *NPM-ALK*^*+*^ cells have impaired tumor formation.^[@bib129]^ These advances in the genomics and proteomics of ALCL have enabled new therapeutic approaches. Combining new and less-toxic therapies offers exciting opportunities to enhance the efficacy and safety of therapies for future ALCL patients.

PTCL-NOS in children and adolescents
====================================

PTCLs are a heterogeneous group of cancers arising from mature T and NK cells. These diseases include all forms of T-cell lymphoma except T-lymphoblastic disease. PTCL-NOS is the second most common PTCL after ALCL. In children, PTCL-NOS accounts for about 1% of NHL cases.^[@bib130]^ In contrast, it comprises about 4% of adult NHL.^[@bib131]^

The biology of PTCL-NOS shows great diversity. Identifying the normal cells that correspond to the cellular origin of different PTCL-NOS diseases has been challenging. Several pan-T-cell antigens, as well as cytotoxic and activated T-cell markers, are seen across different T-cell developmental stages.^[@bib132]^ Although several cytogenetic abnormalities have been observed in PTCL-NOS, a specific schema of clinically useful classification has not been established.^[@bib133]^ In fact, *ALK* translocations in ALCL represent the only recurrent genetic aberration in PTCL.^[@bib134]^ Furthermore, apart from the frequent clonal TCR rearrangements seen in PTCL-NOS, other molecular changes vary and display no consistent pattern.^[@bib3]^

Recent studies in PTCL-NOS biology have led to exciting findings. Genomic analyses of tumor specimens have linked reduced expression of *NF-κB* genes to shortened survival.^[@bib135]^ Another report used expression profiling to stratify PTCL-NOS into three subgroups: one notable for cyclin D2 expression, another with NF-κB1 and BCL-2 overexpression, and a third with high expression of genes in the interferon/Janus kinase/signal transducers and activators of transcription pathway.^[@bib136]^ Although further studies are needed to confirm these results and deepen our understanding as pertains to lymphomagenesis, they represent potentially important biological observations in PTCL-NOS.

The clinical presentations of PTCL-NOS can be as varied as its biological characteristics. Patients often exhibit generalized lymphadenopathy (frequently cervical) or extranodal disease of the liver, spleen, skin, and marrow. Most patients have advanced stage disease with high LDH at diagnosis, as well as B-symptoms like fever, night sweats, and/or weight loss. These features derive from increased cytokine production by malignant T cells, and can even cause the hyper-inflammatory signs of hemophagocytic syndrome.^[@bib3]^

Treatment strategies for PTCL, including PTCL-NOS, are similarly varied. It has been challenging to develop and establish effective regimens because clinical experience in pediatric PTCL is sparse and individual studies are hampered by too few patients. Overall, while a few PTCL types require unique approaches (for example, adult T-cell leukemia/lymphoma (ATLL) and Epstein--Barr virus (EBV)-positive T-cell lymphoproliferative disease (T-LPD) of childhood, ALCL, and some cutaneous entities), other PTCL patients receive similar therapies irrespective of subtype.

The largest pediatric PTCL cohorts are studies from the USA and the UK. The COG analyzed 20 pediatric patients over a 9-year period. This cohort had 12 PTCL-NOS patients; other diagnoses included extranodal NK/T-cell lymphoma nasal type, subcutaneous panniculitis-like T-cell lymphoma (SPTCL), and enteropathy-type T-cell lymphoma. Treatments varied based upon clinical staging. Advanced stage III--IV disease received a regimen of doxorubicin, prednisone, vincristine, mercaptopurine, and MTX ± alternating therapy with high-dose cytarabine and intermediate-dose MTX. Localized stage I--II patients were treated with CHOP. Patients with localized disease fared well; only 2 relapsed and 9/10 survived. In advanced disease cases, 6/10 relapsed and only 5 survived. These results are markedly better than typically seen in adults with PTCL. However, while CHOP seems adequate for localized cases, the 50% OS of advanced stage patients leaves room for improvement.^[@bib137]^

The UK experience was similar. This study retrospectively analyzed 25 PTCL cases in children and adolescents over 20 years. A similar distribution of PTCL subtypes was seen with 68% categorized as PTCL-NOS. Remaining diagnoses included angioimmunoblastic T-cell lymphoma (AITL), angiocentric PTCL, and SPTCL. Patients received either B-NHL CHOP-like regimens or T-ALL therapy. In children with PTCL-NOS, 9/12 survived after T-ALL therapy, but 4/5 died following B-NHL treatment. Like the COG study, when analyzed by extent of disease, most patients (9/12) with local stage I--II disease survived, but only 6/12 advanced stage patients survived. The authors concluded that T-ALL therapy was appropriate for children with PTCL-NOS, but prognoses for children with advanced stage disease remain guarded.^[@bib130]^

Adults with PTCL generally have inferior outcome. Five-year OS in adult studies ranges from 25 to 45% with many treatment strategies used.^[@bib3],\ [@bib138],\ [@bib139],\ [@bib140]^ Chemotherapy regimens for adults frequently include CHOP-like therapy, and incorporation of cytarabine, cisplatin, and etoposide have not bolstered survival rates. Owing to poor outcomes, high-dose chemotherapy followed by auto- or allo-SCT has also been explored. High-dose chemotherapy with auto-SCT has been attempted in both the initial diagnosis and relapse setting. In patients with refractory or recurrent disease, OS after auto-SCT is about 33%.^[@bib141]^ Some studies report slightly higher OS rates of 39--48%, but these cohorts included ALCL patients, who typically do well with auto-SCT salvage therapy. When separated out, non-ALCL PTCL cases had OS closer to 30% in these same studies.^[@bib142]^ Attempts with front-line auto-SCT in newly diagnosed PTCL have yielded only marginally better results. A large Italian study in high-risk PTCL patients who received up-front auto-SCT reported long-term OS rates of 39%. OS was hampered by the fact that many patients progressed before auto-SCT and never received transplant. But, in patients who did receive high-dose chemo and auto-SCT, 12-year disease-free survival rate was improved to 55%.^[@bib143]^

Allo-SCT has also been used in high-risk PTCL. This strategy provides the advantages of infusing a known lymphoma-free graft, as well as potential graft-vs-lymphoma effect. Although patients receiving allo-SCT have proven lower relapse risks (compared with auto-SCT), historically high rates of transplant-related mortality in fully ablative conditioning regimens have offset any survival advantage.^[@bib144]^ Better success has been achieved using allo-SCT with reduced intensity conditioning regimens. In a pilot study of 17 patients with refractory and recurrent disease (eight after failed auto-SCT), 3-year progression-free survival was 64%, and only one patient experienced transplant-related mortality.^[@bib145]^ These results offer hope for this notoriously recalcitrant disease.

Establishing prognostic criteria for high-risk PTCL is important to identify patients who may be candidates for intensified treatment. As mentioned above, pediatric studies show patients with advanced stage III--IV disease have markedly worse outcomes than localized stage I--II disease.^[@bib130],\ [@bib137]^ In adults, the International Prognostic Index (IPI) provides risk stratification. The IPI incorporates features such as stage, LDH level, patient age, multifocal extranodal disease involvement, and performance status. Its validity in adult PTCL-NOS patients was verified in a Canadian study of 117 patients. Those with an IPI score of 0--1 (30% of the cohort) had 64% 5-year OS, while those with IPI \>2 (70% of patients) had OS of only 30%.^[@bib140]^ A Prognostic Index for PTCL-NOS (PIT) model was established based on IPI principles and results from a series of nearly 400 patients. Four variables were used to stratify prognostic groups: age, performance, LDH, and marrow involvement. Five-year OS rates by PIT score were: 0, 62% 1, 53% 2, 33% and \>2, 18%.^[@bib146]^ In applying this schema to pediatric patients, advanced disease markers like high LDH and marrow involvement would portend worse prognoses.

Considering the poor outcomes of high-risk PTCL patients, new therapeutic strategies are desperately needed. Agents being investigated include compounds from various pharmacological classes including nucleoside analogs, antifolates, histone deacetylase and proteasome inhibitors, anti-angiogenesis agents, and monoclonal antibodies. Of nucleoside analogs, pentostatin and gemcitabine have been most promising. A single institution study of 10 patients demonstrated 60% ORR to gemcitabine with refractory/recurrent disease.^[@bib147]^ Nelarabine, on the other hand, achieved only 11% ORR and showed marked toxicity.^[@bib148]^ The histone deacetylase-inhibitor depsipeptide showed a 26% ORR in a phase II trial,^[@bib149]^ and the anti-angiogenic bevacizumab has induced CR in case reports of refractory/recurrent AITL.^[@bib150],\ [@bib151]^ Pralatrexate, an anti-folate, has shown promise in phase I--II trials with 47% ORR in 26 patients with T-cell lymphoma, many with PTCL-NOS.^[@bib152]^ This work has expanded to a multicenter trial, and interim data show a 29% ORR in 65 patients, with 11% of patients achieving CR.^[@bib153]^ Combining liposomal doxorubicin with the proteasome inhibitor bortezomib has proven safe and effective in other advanced hematological malignancies.^[@bib154]^ Proteasome inhibitors promote apoptosis and other anti-proliferative properties by inhibiting the NF-κB pathway. Bortezomib thus is an attractive candidate drug for PTCL-NOS diseases with demonstrated overexpression of *NF-κB1* target genes.^[@bib136]^ Bortezomib has also been studied in refractory and relapsed cutaneous T-cell lymphomas, where 67% ORR was seen with single-agent therapy. Although most cases in that trial were mycosis fungoides, one of two PTCL-NOS patients also responded.^[@bib155]^ Current efforts add bortezomib to first-line PTCL agents,^[@bib156]^ with *in vitro* testing of cutaneous PTCL demonstrating synergy between bortezomib and the histone deacetylase inhibitor suberoylanilide hydroxamic acid.^[@bib157]^

Monoclonal antibody therapies have gained considerable momentum in the treatment of pediatric lymphomas over the past decade. These successes have fostered interest evaluating them in PTCL as well. Alemtuzumab is a humanized monoclonal antibody targeting CD52, an antigen expressed on most lymphocytes. It showed a 36% ORR as a single agent in a pilot study of 14 patients with refractory/recurrent PTCL. However, excessive infectious complications prompted premature closure of this study after five patients suffered from treatment-related mortality.^[@bib158]^ More recently, alemtuzumab was combined with CHOP as front-line therapy. This regimen had 41% 1-year EFS, with an acceptable toxicity profile.^[@bib159]^ Other monoclonal antibodies have been explored in cutaneous T-cell lymphomas and their role in PTCL is unclear. These include the anti-CD4 antibody zanolimumab, and the anti-CD25 antibodies daclizumab and denileukin diftitox.^[@bib160],\ [@bib161]^ Despite this wide arsenal of novel therapeutics and the guardedly optimistic results achieved by reduced intensity allo-SCT in PTCL, it remains crucial to pursue the biologic underpinnings of these diseases. Given their rare occurrence, it is unlikely they will ever be amenable to large-scale clinical trials to empirically test all possible therapies. It will therefore continue to be important to identify biological markers that provide scientific rationale to help guide treatment choices that optimize therapeutic outcomes for this challenging and diverse group of patients.

Rare T- and NK-cell lymphomas in children and adolescents
=========================================================

A number of rare lymphomas originating from mature T and NK cells account for an incredibly diverse spectrum of malignancies ([Figure 1](#fig1){ref-type="fig"}).^[@bib162]^ These lymphomas vary widely by geography and ethnicity with a considerably higher prevalence in Asia.^[@bib131]^ Although certain diseases have well-described etiologies (for example, human T-cell lymphotropic virus-1 (HTLV-1) in ATLL and EBV in EBV^+^ T-LPD), for most rare T- and NK-cell lymphoams, a link is not determined.^[@bib3]^

Over 20 mature T- and NK-cell lymphomas are listed in [Table 1](#tbl1){ref-type="table"}. The 2008 WHO Classification of Lymphoid Neoplasms subdivides T- and NK-cell lymphomas into four clinical presentation-based groups: leukemic/disseminated, extranodal, extranodal-cutaneous, and nodal. Among mature T- and NK-cell lymphomas, the leukemic/disseminated group includes HTLV-1^+^ ATLL and systemic EBV^+^ T-cell LPD of childhood. Extranodal diseases include extranodal NK/T-cell lymphoma, hepatosplenic lymphoma, enteropathy-associated T-cell lymphoma, and others. Cutaneous forms include mycosis fungoides/Sezary syndrome, primary cutaneous CD30^+^ LPD (discussed previously with ALCL), SPTCL, and primary cutaneous gamma/delta (γ/δ) T-cell lymphoma. Nodal entities include ALCL, AITL, and PTCL-NOS. The remainder of this review will discuss several rare T- and NK-cell lymphomas in children and adolescents.

Hepatosplenic γ/δ T-cell lymphoma
---------------------------------

Characterized by involvement of liver, spleen, and marrow, hepatosplenic γ/δ T-cell lymphoma is a rare and aggressive peripheral T-cell neoplasm. It is a disease of young adults with distinct male predominance. Marked hepatosplenomegaly with frequent marrow infiltration is typical, and patients notably present without lymphadenopathy. Up to 20% of cases arise in patients with chronic immune suppression, often after solid organ transplantation or prolonged exposure to azathioprine and infliximab. Recently, EBV-negative T-cell lymphomas with features of hepatosplenic T-cell disease were reported in inflammatory bowel disease patients receiving infliximab.^[@bib163]^ Karyotypic studies consistently show isochromosome 7q, often with trisomy 8, and TCR rearrangements. Expression profiling showed high levels of NK-cell messages such as killer cell immunoglobulin-like and lectin-like receptors, compared with PTCL specimens with α/β phenotype.^[@bib164]^ Ontology analysis revealed enrichment of genetic pathways for cellular defense responses, signal transduction, receptor activity, transmembrane receptor activity, and immunoglobulin G binding. Prognosis is grim, as most patients experience recurrent disease after brief responses to conventional chemotherapy.^[@bib165]^ Long-term remissions have been reported in pediatric and adult patients receiving allo-SCT.^[@bib166],\ [@bib167]^

Subcutaneous panniculitis-like T-cell lymphoma
----------------------------------------------

The characteristic presentation of subcutaneous lesions distinguishes SPTCL. Although more common in adults, there are several reports of SPTCL in children and adolescents. Patients present with atypical T-cell infiltrations confined to subcutaneous tissues, resulting in panniculitic-appearing skin nodules and/or ulcerated lesions. SPTCL is usually local, with organ or node involvement uncommon. Clinical courses can be protracted or aggressive, and patients may present with symptoms of hemophagocytic syndrome.^[@bib168]^ T-cell phenotyping has delineated two distinct entities. The α/β type is more common and differs from the ominous primary cutaneous γ/δ T-cell lymphoma. Cutaneous γ/δ disease has similar clinical features to SPTCL, but is considered a variant of the hepatosplenic γ/δ T-cell lymphomas discussed above. α/β SPTCL and cutaneous γ/δ disease have different immunophenotypes (α/β: CD8^+^56^−^/βF1^+^; γ/δ: CD8^−^56^+^/βF1^−^), and α/β disease has less frequent features of hemophagocytosis and markedly better outcome. Patients with α/β SPTCL have been treated with multi-agent regimens with reasonable efficacy, whereas patients with cutaneous γ/δ disease have poor outcomes like cases of γ/δ hepatosplenic lymphoma.^[@bib169]^

EBV-positive T-cell lymphoproliferative disorders
-------------------------------------------------

The 2008 WHO classification incorporated two types of EBV-associated T-cell LPD affecting the pediatric population: systemic EBV^+^ T-cell LPD of childhood and hydroa vacciniforme-like T-cell lymphoma. Both diseases occur predominantly in Asians and individuals of Native American descent from various regions of Latin America.

Systemic EBV-positive T-cell LPD of childhood
---------------------------------------------

Most patients present with symptoms of a systemic hyper-inflammatory response with disease mimicking the presentation of hemophagocytic lymphohistiocytosis. Acute onset of fever and malaise often precedes the eventual development of hepatosplenomegaly and liver failure, with or without lymphadenopathy. This disease has rapid progression to multi-organ failure, hemophagocytic syndrome and death. Chronic active EBV infection has been documented in some patients before developing EBV^+^ T-cell LPD, but most cases are fulminant and arise with acute primary EBV infection. Fulminant cases are CD8^+^, whereas chronic active EBV-associated cases are CD4^+^. EBV-encoded RNA-1 is positive in neoplastic T cells that exhibit clonal TCR gene rearrangement and harbor EBV in a clonal episomal form. This severe illness is characterized by clonal proliferation of EBV-infected T cells with an activated cytotoxic phenotype. All cases are type A EBV, with either the wild type or a specific 30 base pair-deletion of the viral *LMP1* gene. Frequent sites of involvement include liver, spleen, nodes, and marrow. The typical immunophenotype of tumor cells is CD2^+^CD3^+^CD56^−^. Transient chemotherapy responses are reported, but almost all cases have rapid disease progression ending in death.^[@bib170]^

Hydroa vacciniforme-like lymphoma
---------------------------------

Hydroa vacciniforme-like T-cell lymphoma is an EBV^+^ cutaneous malignancy occurring mostly in children. Linked to sun sensitivity, this condition primarily affects sun-exposed skin, and the face in particular. Papulovesicular eruptions precede ulceration and scarring. The clinical course is variable and skin lesions may be recurrent. Late in the disease, systemic symptoms develop such as fever, wasting, lymphadenopathy, and hepatosplenomegaly. Similar to EBV^+^ T-cell LPD, neoplastic cells have clonal TCR rearrangements and harbor EBV in a clonal episomal form. It is not clear whether the severe mosquito-bite allergy seen in chronic active EBV infection, which has similar cutaneous lesions of NK-cell derivation, is related to the hydroa vacciniforme-like lymphoma or a distinct entity in the spectrum of EBV-associated disorders. Both diseases are considered part of the spectrum of severe chronic active EBV, demonstrating a broad variation in clinical aggressiveness.^[@bib171]^ Allo-SCT provides the only curative option for patients, but it remains to be seen whether novel EBV-specific cytotoxic T-lymphocyte (CTL) immunotherapies have a role in this unique disorder.^[@bib172]^

Adult T-cell leukemia/lymphoma
------------------------------

ATLL is another rare T-cell malignancy associated with viral infection. It is associated with HTLV-1 infection, a virus endemic to regions including Japan, the Caribbean, parts of South America, West and Central Africa, and some of the Oceanic Islands.^[@bib173]^ Infection with the HTLV-1 retrovirus carries an approximate 5% lifetime risk of developing ATLL.^[@bib174]^ Although trophic for CD4^+^ T cells, HTLV-1 infection does not cause cytopathic destruction of CD4^+^ T cells. Rather, upon integration, it governs its own transcription using its regulatory protein Tax. Tax interacts with host proteins that can promote lymphomagenesis including the NF-κB pathway,^[@bib175]^ trans-activating proteins that promote T-cell proliferation and apoptosis inhibition, proteins repressing cell cycle control and DNA repair, and multiple tumor suppressors.^[@bib176]^ A second retroviral protein, HBZ, is also linked to the NF-κB^[@bib177]^ and T-cell proliferation pathways.^[@bib178]^ These retroviral proteins contribute to HTLV-1 pathogenesis, but the virus itself is not considered to be directly oncogenic. HTLV-1 infection induces humoral and cellular immune responses, and like EBV-induced lymphomas, impaired anti-HTLV-1 CTL responses are associated with ATLL.^[@bib179],\ [@bib180],\ [@bib181]^

There are four clinical variants of ATLL: acute, lymphomatous, chronic, and smoldering. Acute is most common, with patients presenting with disseminated disease, systemic symptoms, organomegaly, and circulating malignant cells. The ATLL immunophenotype is usually CD2^+^/4^+^/5^+^/25^+^, with loss of pan-T marker CD7. CD8^+^ variants also exist.^[@bib182]^ ATLL patients are typically immunocompromised with increased risk of opportunistic infection. Prognosis for acute and lymphomatous ATLL is dismal with median survival \<1 year using standard chemotherapy.^[@bib183]^ Evidence for a link between HTLV-1 and ATLL is substantiated by improved prognosis (30--40% survival) in patients treated with allo-SCT.^[@bib184]^ Clearance of HTLV-1 proviral loads and suggestion of a graft-vs-lymphoma effect have been documented in multiple clinical trials, revealing promise for this immunotherapeutic approach.^[@bib185]^

Extranodal NK/T-cell lymphoma
-----------------------------

Extremely rare in the western hemisphere, extranodal NK/T-cell lymphoma occurs primarily in Far and Southeastern Asia. The majority of cases (60--90%) present with nasal or upper airway masses, but extranasal disease is also described. Virtually all cases are EBV^+^, with cytoplasmic CD3 and CD56 surface expression. Most cases also test positive for cytotoxic proteins such as TIA-1, granzyme B, and perforin.^[@bib186]^ Genomic profiling studies have shown several genomic losses and gains associated with NK-cell malignancies---deletion in 6q21 being most common.^[@bib187]^ Meanwhile, expression profiling reveals high transcript levels for genes in the p53 pathway, anti-apoptosis pathways, and cytokine receptors in NK lymphoma cell lines as compared with normal NK cells. A tandem mass spectrometry-based proteomic analysis established overexpression of potential targets implicated in disease pathogenesis, including HSP90 and proliferating cell nuclear antigen. Moreover, *in vitro* inhibition of HSP90 with geldanamycin demonstrates reduced cell viability and increased apoptosis.^[@bib188]^ NK-cell lymphomas are very aggressive and have poor outcomes, with 5-year OS of 32% in recent studies. Of note, extranasal NK disease has strikingly worse prognosis (9% 5-year OS) vs the more common nasal type (42% 5-year OS).^[@bib189]^

Angioimmunoblastic T-cell lymphoma
----------------------------------

In contrast to the extranodal presentation of NK-cell lymphoma, AITL usually presents with lymphadenopathy. Clinical hallmarks include systemic disease features, with most patients manifesting generalized lymphadenopathy, B symptoms, elevated LDH, and hepatosplenomegaly. Many patients also present with pruritic skin rash. EBV and human herpesvirus-6 are detectable in many cases, but the implications of these findings are not clear.^[@bib190]^ Histologically, AITL is characterized by proliferation of high endothelial venules and follicular dendritic cells. Tumors arise from CD4^+^ cells belonging to the follicular helper T-cell lineage.^[@bib191]^ Determination of AITL molecular signatures has yielded a classifier schema comprised of three prominent patterns: a B-cell signature, a follicular dendritic-cell signature, and a cytokine signature, reflecting the relationship between the tumor cells and their microenvironment. Gene expression analyses in AITL show activation of the NFκB pathway and enrichment of genes denoting dendritic cell function and interleukin-6 signaling. Importantly, this study identified prognostic features predictive of poor outcome in the form of gene signatures reflecting immunosuppression: tolerogenic dendritic cells and CD31^−^ stromal cells. Additionally, involvement of NFκB may provide a potential means to develop novel treatments. Like extranodal NK-cell lymphoma cases, AITL patients have poor survival outcomes with 5-year OS approximating 30%.^[@bib192]^

Rare T- and NK-cell lymphomas summary
-------------------------------------

Ultimately, PTCL lymphomas remain a diagnostic and therapeutic challenge. Although biologic studies have been performed in adult series, the rarity of pediatric PTCL cases hinders large-scale investigations on both the basic science and clinical fronts. To address this problem, COG has initiated collection of rare pediatric lymphomas and LPDs via study ANHL04B1. A central institutional review board facilitates prompt patient enrollment and expedited pathologic review of specimens to confirm these scarce diagnoses by a three-expert hematopathology panel. This study also gathers information regarding therapy chosen by the treating physicians and outcome. As these cases require individualized care, no specific therapy is linked to the ANHL04B1 study. Instead, its aim is to collect diagnostic, treatment, and outcome data on these rare diseases in children and adolescents. Meanwhile, as new therapeutics are continually tested in adults, it is likely that extrapolation from these studies will be necessary to improve outcomes in rare pediatric cases. As our biologic understanding of these diseases advances and new targets emerge, therapies will become more enlightened. Until such regimens have been proven, children with all subtypes of advanced stage, refractory, and recurrent PTCL may benefit from induction therapy followed by allo-SCT with reduced intensity conditioning regimens.

Conclusion
==========

T- and NK-cell lymphomas in pediatric patients are a complex group of neoplasms arising from precursor T lymphoblasts or other mature T- and NK-cell subsets. T-LBL is the most common, representing one-third of childhood and adolescent NHL. Although the genomic and genetic underpinnings of T-ALL have been thoroughly scrutinized, much less is known about T-LBL molecular pathogenesis. It has been generally accepted that T-ALL and T-LBL are different manifestations of the same disease, but recent studies show that T-ALL and T-LBL have distinct genetic aberrations and non-identical expression patterns. Advances in T-ALL biology have led to novel therapeutics currently under investigation, but a deeper understanding of T-LBL and its relation to T-ALL is needed to enhance treatment outcomes for these patients. Among mature T-cell neoplasms, *ALK*^*+*^ ALCL is most prevalent. The genetic aberration defining this disease is, logically, a target for therapeutic intervention. *ALK* tyrosine kinase inhibitors are currently being tested in relapsed ALCL. Pediatric PTCLs arising from mature T cells are so rare that they are challenging to study. However, our increasing knowledge of their biologic features, coupled with attention to adult treatment strategies, will undoubtedly offer insights for pediatric PTCL. As our understanding of PTCL molecular pathogenesis continues to grow, there is cause for optimism. Ultimately, there is no inherent reason why childhood and adolescent T- and NK-cell lymphomas should not be equally curable to other pediatric lymphocyte cancers like HL, B-NHL, and ALL.
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![Montage of pathology images for several different T- and NK- cell lymphomas in children and adolescents. (**a**) T-LBL showing diffuse infiltration of T-lymphoblasts with fine nuclear chromatin and scarce cytoplasm. Blasts have inconspicuous nucleoli and irregular nuclear contours. × 200 magnification, hematoxylin and eosin (H&E) stain. (**b**) ALCL, *ALK*^*+*^, showing large neoplastic cells with marked pleomorphism and abundant cytoplasm. Characteristic horseshoe-shaped cells are seen. Cells stained strongly with CD30 and ALK antibodies demonstrate a mature T-cell immunophenotype. × 400 magnification, H&E. (**c**) PTCL, NOS with predominantly large cell morphology. Neoplastic cells are large with abundant cytoplasm and variably prominent nucleoli. Immunophenotyping reveals a mature T-cell phenotype, but cells lack expression of CD30 or ALK. × 400 magnification, H&E. (**d**) Hepatosplenic γ/δ T-cell lymphoma. Small-to-intermediate neoplastic cells have infiltrated liver sinusoids. These cells show round nuclear contours, clumped chromatin without prominent nucleoli, and abundant clear cytoplasm. × 100 magnification, H&E. (**e**) SPTCL demonstrating invasion of malignant cells into fat. Small-to-intermediate size neoplastic cells with moderate cytologic atypia and irregular nuclear contours surround fat lobules. × 400 magnification, H&E. (**f**) Primary cutaneous γ/δ T-cell lymphoma that presented with skin nodules and plaques with extensive dermal involvement and extension into panniculitic fat. Medium-to-large neoplastic cells have occasional prominent nucleoli. Neoplastic cells lacked CD4 and CD8 expression and were EBV negative. × 200 magnification, H&E. (**g**) T-cell post-transplant lymphoproliferative disorder in a patient with liver transplant 2 years prior. Clonal T cells have invaded the intestine and are EBV positive. × 400 magnification, H&E. (**h**) Extranodal T/NK-cell lymphoma of the nasal cavity showing angiocentric pattern with vascular invasion. Neoplastic cells are small-to-intermediate in size with abundant cytoplasm. Irregular nuclei show clumped hyperchromatic chromatin. Cells are CD8 and EBV positive. × 200 magnification, H&E. (**i**) AITL with diffuse nodal effacement and prominent arborizing vessels. Neoplastic cells are intermediate size and show variable clear cytoplasm. × 200 magnification, H&E.](bcj20128f1){#fig1}

![Time and site of disease recurrence in children with relapsed lymphoblastic lymphoma. I, patients with T-LBL; X, patients with precursor B-cell lymphoblastic lymphoma; BM, bone marrow. (^\*^) Patient was treated on a high-risk arm and experienced relapse during an intensive phase of treatment 11 months after start of therapy. Reprinted from Burkhardt*et al.*^[@bib10]^](bcj20128f2){#fig2}

![Prevalence, degree, and impact of marrow involvement in children with T-cell lymphoblastic lymphoma (T-LL). (**a**) Percentage of T-LL cells in bone marrow at diagnosis as detected by flow cytometry, according to disease stage based on conventional criteria. Horizontal bars indicate median value for each group. (**b**) Event-free survival stratified by level of T-LL cells in bone marrow at diagnosis as measured by flow cytometry: \<5% and ⩾5% T-LL cells. Reprinted from Coustan-Smith *et al.*^[@bib39]^](bcj20128f3){#fig3}

![(**a**) Prevalence of minimal residual disease (MRD) during the early phases of therapy for patients with early T-precursor (ETP) vs standard T-ALL. MRD levels were measured by flow cytometry. Horizontal bars indicate median values, if above 0.01%. (**b**) Kaplan--Meier plots showing cumulative incidence of remission failure or hematological relapse in patients with standard T-lymphoblastic leukemia (T-ALL; red) vs early T-precursor (ETP-ALL; blue) treated on St Jude protocols. Curves start at time of diagnosis. Outcome estimates at 10 years of follow-up are shown; *P-*values are from the log-rank test. Reprinted from Coustan-Smith *et al.*^[@bib40]^](bcj20128f4){#fig4}

![Targeted treatment strategies for T-LBL. Glucocorticoid binding causes nuclear translocation of cytoplasmic receptors, which then bind glucocorticoid response elements (GREs) to promote transcription of pro-apoptotic genes, leading to cell death. Other drugs block pathways needed for growth and survival of malignant T-cell lymphoblasts. GSIs prevent release of intracellular notch (ICN1) from membrane-tethered heterodimeric NOTCH1 protein. Combined glucocorticoid and GSI therapies show synergy, but *pten* deletions can subvert reliance upon activated NOTCH1. Inhibitors of phosphatidylinositol 3-kinase (PI3K), AKT, and mTOR counteract this, thereby restoring GSI-sensitivity. One of the activities of ICN1 is to augment NF-κB signaling. Blocking proteosomal degradation can stabilize inhibitors of NF-κB (IκB), allowing Bortezomib to cooperate with GSI as well (figure design by Yaya Chu, New York Medical College).](bcj20128f5){#fig5}

![Model of ALK and CD30 signaling. In ALCL, the NPM--ALK fusion protein governs CD30 expression by phosphorylating signal transducer and activator of transcription 3 (STAT3). NPM--ALK also regulates extracellular signal-regulated kinase 1 (ERK1)- and ERK2-mediated activation of JUNB protein. Phosphorylated STAT3 and activated AP1 complexes containing JUNB then cooperate to enhance *CD30* transcription. NPM--ALK impedes CD30 signaling and NF*κ*B activation by sequestering tumor necrosis factor receptor-associated factor 2 (TRAF2) away from CD30. This occurs via dimerization of NPM-ALK with wild-type (WT) NPM. CD30 engagement normally causes TRAF2 degradation. Engagement of CD30 on ALCL cells results in activation of both the canonical and alternative NFκB pathways, which causes apoptosis and p21-mediated cell-cycle arrest. A clinical trial is testing the use of anti-CD30 antibodies (red arrow) in ALCL109. Reprinted from Chiarle *et al.*^[@bib77]^](bcj20128f6){#fig6}

###### WHO 2008 classification of precursor and mature T/NK-cell neoplasms

  --------------------------------------------------------------------------
  *Leukemic or disseminated*
   T-lymphoblastic leukemia/lymphoma
   T-cell prolymphocytic leukemia
   T-cell large granular lymphocytic leukemia
   Chronic lymphoproliferative disorders of NK cells
   Aggressive NK-cell leukemia
   Adult T-cell leukemia/lymphoma (HTLV1 positive)
   Systemic EBV-positive T-cell lymphoproliferative disorders of childhood
   
  *Extranodal*
   Extranodal NK/T-cell lymphoma, nasal type
   Enteropathy-associated T-cell lymphoma
   Hepatosplenic T-cell lymphoma
   
  *Extranodal-cutaneous*
   Mycosis fungoides
   Sezary syndrome
   Primary cutaneous CD30^+^ lymphoproliferative disorders
    Primary cutaneous anaplastic large cell lymphoma
    Lymphomatoid papulosis
   Subcutaneous panniculitis-like T-cell lymphoma
   Primary cutaneous gamma-delta T-cell lymphoma
   Primary cutaneous aggressive epidermotropic CD8^+^ cytotoxic lymphoma
   
  *Nodal*
   Angioimmunoblastic T-cell lymphoma
   Anaplastic large cell lymphoma, ALK positive
   Anaplastic large cell lymphoma, ALK negative
   Peripheral T-cell lymphoma, NOS
   Primary cutaneous small/medium CD4^+^ T-cell lymphoma
  --------------------------------------------------------------------------

Abbreviations: ALK, anaplastic lymphoma kinase; EBV, Epstein--Barr virus; HTLV1, human T-cell lymphotropic virus-1; NK, natural killer; NOS, not otherwise specified; WHO, World Health Organization.

###### Advanced disease lymphoblastic lymphoma in children

  *Cooperative Gp.*                   *BFM*^[@bib11]^                              *BFM*^[@bib19]^                 *St Jude*^[@bib23]^   *EORTC-CLG*^[@bib22]^   *AIEOP*^[@bib18]^   *CCG*^[@bib20]^
  --------------------- -------------------------------------------- -------------------------------------------- --------------------- ----------------------- ------------------- -----------------
  Patients (*N*)                            101                                          335                               41                     121                   55                 85
  Protocol                               NHL-BFM-90                                   NHL-BFM-95                          NHL13                CLG 58881              LNH-92            CCG 5941
  Duration (months)                          24                                           24                               32                     24                    24                 12
  CRT                                   All patients                                  CNS+ only                           None                   None                CNS+ only          CNS+ only
  CNS-- dose               0 or 12 Gy[a](#t2-fn2){ref-type="fn"}                          NA                              None                   None                   NA                 NA
  CNS+ dose              0, 18, or 24 Gy[a](#t2-fn2){ref-type="fn"}   0, 12, or 18 Gy[b](#t2-fn3){ref-type="fn"}          None                   None                  18 Gy              18 Gy
  EFS (Est) 3-6 years                       90%                                          84%                               83%                    78%                   69%                78%

Abbreviations: AIEOP, Italian Association of Pediatric Hematology and Oncology; BFM, Berlin--Frankfurt--Munster; EORTC-CLG, European Organization for Research and Treatment of Cancer-Children\'s Leukemia Group; CCG, Children\'s Cancer Group; CNS, central nervous system; CRT, cranial radiation therapy; EFS, event-free survival; Est, estimate; LNH, lymphoma non-Hodgkin; NA, not applicable; NHL, non-Hodgkin lymphoma.

On BFM-90, children under 1 year received no CRT, CNS+ children 1--2 years received 18 Gy, and CNS+ children ⩾2 received 24 Gy.

On BFM-95, children under 1 year received no CRT, CNS+ children 1--2 years received 12 Gy, and CNS+ children ⩾2 received 18 Gy.

Reprinted from Cairo.^[@bib5]^

###### Recurrent chromosomal translocations involving ALK in cancers

  *Chromosomal translocation*              *Partner protein*                                         *Frequency (%)*  *Fusion protein (kDa)*   *Cellular localization*            *Type of tumor*                                        *Refs*
  ---------------------------------------- -------------------------------------------------------- ----------------- ------------------------ ---------------------------------- ----------------------------------- --------------------------------------------
  t(2;5)(p23;q35)                          Nucleophosmin (NPM)                                           75--80       NPM--ALK (80)            Nucleus, mucleolus and cytoplasm   ALK^+^ ALCL and ALK^+^ DLBCL         [@bib193], [@bib194], [@bib195], [@bib196]
  t(1;2)(q25;p23)                          Tropomyosin 3 (TPM3)                                          12--18       TPM3--ALK (104)          Cytoplasm                          ALK^+^ ALCL and IMT                       [@bib197], [@bib198], [@bib199]
  t(2;3)(p23;q21)                          TRK-fused gene (TFG)                                             2         TFG--ALK (113,97,85)     Cytoplasm                          ALK^+^ ALCL                                     [@bib200], [@bib201]
  inv(2)(p23;q35)                          ATIC                                                             2         ATIC--ALK (96)           Cytoplasm                          ALK^+^ ALCL and IMT                       [@bib202], [@bib203], [@bib204]
  t(2;17)(p23;q23)                         Clathrin heavy chain-like 1 (CLTC1)                              2         CLTC1--AKL (250)         Granular cytoplasmic               ALK^+^ ALCL, IMT and ALK^+^ DLBCL         [@bib205], [@bib206], [@bib207]
  t(2;X)(p23;q11--12)                      Moesin (MSN)                                                    \<1        MSN--ALK (125)           Cell-membrane associated           ALK^+^ ALCL                                     [@bib208], [@bib209]
  t(2;19)(p23;p13)                         Tropomyosin 4 (TPM4)                                            \<1        TPM4--ALK (95-105)       Cytoplasm                          ALK^+^ ALCL and IMT                             [@bib198], [@bib210]
  t(2;17)(p23;q25)                         ALO17                                                           \<1        ALO17--ALK (ND)          Cytoplasm                          ALK^+^ ALCL                                          [@bib211]
  t(2l2)(p23;q13) or inv(2)(p23;q11--13)   RAN-binding protein 2 (RANBP2)                                  \<1        RANBP2--ALK (160)        Periphery of the nucleus           IMT                                                  [@bib212]
  t(2;22)(p23;q11.2)                       Non-muscle myosin heavy chain (MYH9)                            \<1        MYH9--ALK (220)          Cytoplasm                          ALK^+^ ALCL                                          [@bib213]
  t(2;11;2)(p23;p15;q31)                   Cysteinyl-tRNA synthetase (CARS)                                \<1        CARS--ALK (130)          Unknown                            IMT                                             [@bib211], [@bib214]
  ins(3\'ALK)(4q22--24)                    Unknown                                                         \<1        Unknown                  Granular cytoplasmic               ALK^+^ DLBCL                                         [@bib215]
  t(2;4)(p23;q21)                          SEC31 homologue A (*S.cerevisiae*) (SEC31L1)                    \<1        SEC31L1--ALK (ND)        Cytoplasm                          IMT                                                  [@bib216]
  inv(2)(p21;p23)                          Echinoderm microtubule-associated protein-like4 (EML4)           6         EML4--ALK (ND)           Unknown                            NSCLC                                                [@bib217]

Abbreviations: ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ALO17, ALK lymphoma oligomerization partner on chromosome 17; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; DLBCL, diffuse large B-cell lymphoma; IMT, inflammatory myofibroblastic tumors; ND, not determined; NSCLC, non-small-cell lung cancer; Refs, references.

Reprinted from Chiarle *et al.*^[@bib77]^

###### Advanced anaplastic large cell lymphoma in children

                          *BFM*^[@bib89]^   *POG*^[@bib92]^   *SFOP*^[@bib91]^   *St Jude*^[@bib90]^   *MSKCC*^[@bib107]^   *CCG*^[@bib93]^           *BFM, SFOP, and UKCCSG*^[@bib86]^            *EICNHL*^[@bib98]^
  ---------------------- ----------------- ----------------- ------------------ --------------------- -------------------- ----------------- ---------------------------------------------------- ---------------------
  Patients (*N*)                89                67                 82                  18                    19                 86                                 225                                   352
  Protocol(s)               NHL-BFM-90         POG 9315           HM89--91           CHOP-based        LSA~2~L~2~, LSA~4~      CCG-5941       BFM-86 and 90, SFOP HM89 and 91, and UKCCSG 9001-3   Modified NHL-BFM-90
  Duration (months)            2--5               12                7--8                6--18                14--36               12                                 2--8                                 4--12
  EFS (Est) 2--5 years          76%               73%               66%                  57%                  56%                 68%                                69%                                   75%
  OS 2--5 years                 NR                93%               83%                  84%                  84%                 80%                                81%                                   94%

Abbreviations: BFM, Berlin--Frankfurt--Munster; CCG, Children\'s Cancer Group; EICNHL, European Intergroup for Childhood NHL; EFS, event-free survival; Est, estimate; MSKCC, Memorial Sloan Kettering Cancer Center; NHL, non-Hodgkin lymphoma; OS, overall survival; POG, Pediatric Oncology Group; SFOP, French Pediatric Oncology Group; UKCCSG, United Kingdom Children\'s Cancer Study Group.

Adapted from Cairo.^[@bib5]^

[^1]: Equal primary and first authorship contribution.
